KALA BIO (NASDAQ:KALA – Get Free Report) and Celularity (NASDAQ:CELU – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.
Earnings & Valuation
This table compares KALA BIO and Celularity”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| KALA BIO | N/A | N/A | -$38.51 million | ($5.93) | -0.03 |
| Celularity | $54.22 million | 0.74 | -$57.89 million | ($3.33) | -0.42 |
Insider & Institutional Ownership
24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Comparatively, 17.3% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares KALA BIO and Celularity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| KALA BIO | N/A | -2,323.94% | -86.99% |
| Celularity | -198.75% | N/A | -65.03% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for KALA BIO and Celularity, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| KALA BIO | 1 | 4 | 1 | 0 | 2.00 |
| Celularity | 1 | 0 | 1 | 0 | 2.00 |
KALA BIO presently has a consensus target price of $20.38, indicating a potential upside of 12,531.74%. Celularity has a consensus target price of $6.00, indicating a potential upside of 331.65%. Given KALA BIO’s higher probable upside, research analysts clearly believe KALA BIO is more favorable than Celularity.
Volatility & Risk
KALA BIO has a beta of -1.98, indicating that its share price is 298% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.
Summary
Celularity beats KALA BIO on 6 of the 11 factors compared between the two stocks.
About KALA BIO
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
About Celularity
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
Receive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.
